Stifel Financial’s Aimmune Therapeutics AIMT Stock Holding History

Stifel Financial’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-9,651	Closed	-$332K	–	3173
2020 Q3	$332K	Sell	9,651 -15,990	-62%	-$341K	﹤0.01%	2331
2020 Q2	$428K	Sell	25,641 -4,222	-14%	-$71.7K	﹤0.01%	2146
2020 Q1	$431K	Sell	29,863 -5,194	-15%	-$133K	﹤0.01%	1959
2019 Q4	$1.17M	Buy	35,057 +11,793	+51%	+$330K	﹤0.01%	1705
2019 Q3	$488K	Buy	+23,264	New	+$475K	﹤0.01%	2185
2018 Q3	–	Sell	-28,250	Closed	-$756K	–	2853
2018 Q2	$756K	Buy	28,250 +4,725	+20%	+$145K	﹤0.01%	1799
2018 Q1	$752K	Buy	+23,525	New	+$828K	﹤0.01%	1742

Stifel Financial's AIMT Position: Q4 2020 in Review

Stifel Financial sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 9,651 shares — an estimated $332K sold.

Stifel Financial first reported a position in AIMT in Q1 2018 and held it in 7 quarters. The position peaked at $1.17M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Stifel Financial reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Stifel Financial sold 9,651 Aimmune Therapeutics shares in Q4 2020, an estimated $332K.
Stifel Financial first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 7 quarters.
Stifel Financial's Aimmune Therapeutics position peaked at $1.17M in Q4 2019.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Stifel Financial's 13F filing for Q4 2020, filed 12 Feb 2021.